<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">Hyperhomocysteinemia</z:e> is associated with atherosclerotic risk </plain></SENT>
<SENT sid="1" pm="."><plain>Although vitamins can lower <z:chebi fb="0" ids="17230">homocysteine</z:chebi> (<z:chebi fb="0" ids="17230">Hcy</z:chebi>), information about effects on <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> is scarce </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We used carotid intima-media thickness (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>) as an accepted marker of atherosclerotic changes </plain></SENT>
<SENT sid="3" pm="."><plain>Fifty patients (60 +/- 8 years) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>&gt; or =1 mm were included </plain></SENT>
<SENT sid="4" pm="."><plain>In a double blind, randomized trial they received daily 2.5 mg <z:chebi fb="9" ids="27470">folic acid</z:chebi>, 25 mg <z:chebi fb="14" ids="27306">Vitamin B6</z:chebi>, and 0.5mg <z:chebi fb="9" ids="17439">Vitamin B12</z:chebi> or placebo for 1 year </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In the treatment group, <z:chebi fb="0" ids="17230">Hcy</z:chebi> decreased from 10.50 +/- 3.93 to 6.56 +/- 1.53 micromol/l (P &lt; 0.0001), whereas it remained unchanged in the placebo group (10.76 +/- 2.36 versus 10.45+/-3.30 micromol/l) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> decreased from 1.50 +/- 0.44 to 1.42 +/- 0.48 mm (P = 0.034) in the treatment group, whereas it increased from 1.47 +/- 0.57 to 1.54 +/- 0.71 mm in the placebo group </plain></SENT>
<SENT sid="7" pm="."><plain>The mean individual changes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> between both groups differed significantly (-0.08 +/- 0.17 versus 0.07 +/- 0.25 mm, P = 0.019) </plain></SENT>
<SENT sid="8" pm="."><plain>Multiple regression analysis revealed that the observed effect on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> depended only on medication </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Vitamin supplementation significantly reduces <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> in patients at risk </plain></SENT>
<SENT sid="10" pm="."><plain>This effect is independent of <z:chebi fb="0" ids="17230">Hcy</z:chebi> concentration </plain></SENT>
</text></document>